Immunotherapy: Understanding Safety and Pharmacology

Guest editors: Miriam Canavese and Micaela Harrasser · IUSP-20Its last articles are still in review; they appear here as they are published.

This call no longer takes submissions. Looking for one that does? See the open calls in all journals.

Important dates

Call opens15 Apr 2019 · done
Submission deadline31 Aug 2020 · done
Collection complete30 Nov 2020 · done

About this special issue

Cancer immunotherapy attempts to stimulate the immune system to destroy cancer cells. Recently Immunotherapy became of great interest to the scientific community, since it was found particularly promising to treat cancer and it represents the most targeted therapy of all. Authors offering original research articles, review papers featuring timely issues or topics are invited to submit. Topics spanning immunotherapy may include but are not limited to: Antibody-based therapy to treat cancer. CAR T-Cell Therapies. Immune checkpoint inhibitors to treat cancer. Cancer vaccines. Editors encourage discussion on evaluation of safety and pharmacology of immunotherapy.

Guest editors

Miriam Canavese · lead guest editorScientific Director and Head of Immuno-Pharmacology, Freeline Therapeutics, UK
Micaela HarrasserResearcher, University College London, UK

Published so far

Each accepted article is published in the journal’s next regular issue as soon as its author approves the proof, and appears here.

No articles yetThe first articles appear here when they are published.